Vitamin B6 is essential for serine de novo biosynthesis

Rúben J. Ramos¹ · Mia L. Pras-Raves¹ · Johan Gerrits¹ · Maria van der Ham¹ · Marcel Willemsen¹ · Hubertus Prinsen¹ · Boudewijn Burgering² · Judith J. Jans¹ · Nanda M. Verhoeven-Duif¹

Received: 24 February 2017 / Revised: 29 May 2017 / Accepted: 31 May 2017 / Published online: 11 August 2017
© The Author(s) 2017. This article is an open access publication

Abstract Pyridoxal 5′-phosphate (PLP), the metabolically active form of vitamin B6, plays an essential role in brain metabolism as a cofactor in numerous enzyme reactions. PLP deficiency in brain, either genetic or acquired, results in severe drug-resistant seizures that respond to vitamin B6 supplementation. The pathogenesis of vitamin B6 deficiency is largely unknown. To shed more light on the metabolic consequences of vitamin B6 deficiency in brain, we performed untargeted metabolomics in vitamin B6-deprived Neuro-2a cells. Significant alterations were observed in a range of metabolites. The most surprising observation was a decrease of serine and glycine, two amino acids that are known to be elevated in the plasma of vitamin B6 deficient patients. To investigate the cause of the low concentrations of serine and glycine, a metabolic flux analysis on serine biosynthesis was performed. The metabolic flux results showed that the de novo synthesis of serine was significantly reduced in vitamin B6-deprived cells. In addition, formation of glycine and 5-methyltetrahydrofolate was decreased. Thus, vitamin B6 is essential for serine de novo biosynthesis in neuronal cells, and serine de novo synthesis is critical to maintain intracellular serine and glycine. These findings suggest that serine and glycine concentrations in brain may be deficient in patients with vitamin B6 responsive epilepsy. The low intracellular 5-mTHF concentrations observed in vitro may explain the favourable but so far unexplained response of some patients with pyridoxine-dependent epilepsy to folinic acid supplementation.

Introduction

Pyridoxal 5′-phosphate (PLP), the metabolically active form of vitamin B6, plays a pivotal role in brain metabolism and development (Surtees et al 2006). PLP is an essential cofactor in more than 100 metabolic reactions in humans (Clayton 2006). Most of the PLP-dependent reactions, such as transamination, decarboxylation, deamination, racemization and desulfhydration, are involved in amino acid metabolism (Ebadi 1981; Ueland et al 2015). PLP deficiency, either due to genetic or dietary causes, disrupts the metabolism of neurotransmitters (γ-aminobutyric acid (GABA), dopamine and serotonin), haeme, histamine, amino acids, carbohydrates and nucleotides (da Silva et al 2013; Ueland et al 2015). PLP deficiency, either due to genetic or dietary causes, disrupts the metabolism of neurotransmitters (γ-aminobutyric acid (GABA), dopamine and serotonin), haeme, histamine, amino acids, carbohydrates and nucleotides (da Silva et al 2013; Ueland et al 2015).

Five inborn errors of metabolism are known to affect vitamin B6 concentrations: pyridoxine-dependent epilepsy (α-aminoacidic semialdehyde dehydrogenase (antiquitin) deficiency; OMIM #266100), hyperprolinemia type II (1-pyrroline-5-carboxylate dehydrogenase deficiency; OMIM #239510), pyridox(amine) 5′-phosphate oxidase deficiency (PNPO deficiency; OMIM #610090), hypophosphatasia (tissue non-specific alkaline phosphatase (TNSALP) deficiency; OMIM #241500) and proline synthetase co-transcribed bacterial homologue deficiency (PROSC deficiency; OMIM #604436). These diseases, except for most cases of...
To elucidate the pathogenesis of brain vitamin B6 deficiency, we performed untargeted metabonomics on a neuronal cell model deprived of vitamin B6. Our observations indicate that additional factors next to GABA play a role in the pathogenesis of vitamin B6 deficiency.

Results

To study the consequences of vitamin B6 deficiency in neuronal cells, we developed a model system of vitamin B6-deficient Neuro-2a cells. Neuro-2a cells were cultured in the presence (100 nM) and absence of pyridoxal (PL). Cells were harvested at different time points.

Vitamin B6 restriction results in intracellular PLP deficiency

To establish whether the absence of PL in the medium resulted in intracellular vitamin B6 deficiency, we quantified the intracellular concentrations of PL, pyridoxamine (PM), pyridoxine (PN), the 5′-phosphorylated forms (PLP, PMP and PNP, respectively) and the breakdown product pyridoxic acid (PA) (Fig. S1). PLP concentrations were significantly decreased in cells that were cultured in the absence of vitamin B6 ($P < 0.01$ for all time points, with a 41–75% reduction), compared to 100 nM PL. PL concentrations were relatively conserved, being significantly decreased at $t = 14$ days only ($P < 0.05$). Intracellular PMP concentrations were also decreased ($P < 0.01$ at $t = 7$ and 18 days, with a 48% and 53% reduction, respectively; $P < 0.05$ at $t = 4$ and 14 days, with a 27% and 49% reduction, respectively). PN, PNP, PM and PA were below the limit of quantification (LOQ), for both vitamin B6-deficient and –proficient conditions, at all time points. Thus, absence of PL in the medium leads to decreased concentrations of the active cofactor of vitamin B6, making this model suitable for the study of the consequences of vitamin B6 deficiency on the intracellular metabolome.

Vitamin B6 deficiency alters the metabolome of Neuro-2a cells

We compared the metabolomes of Neuro-2a cells cultured in 0 and 100 nM PL at all time points. By direct-infusion high-resolution mass spectrometry (DI-HRMS) of the extracts we detected 15,765 features (a feature is defined as a mass over charge, $m/z$) of which 62 features in negative scan mode and 83 in positive scan mode were significantly different ($P < 0.05$ after Bonferroni correction) and identified using the Human Metabolome Database (HMDB, www.hmdb.ca). The most significantly altered intracellular metabolites, in positive and negative scan modes, are shown in Tables 1 and 2, respectively. Among others, we observed decreased signals of the masses corresponding to the amino acids serine, glycine and cystathionine, GABA, the Krebs cycle intermediates malate, citrate/isocitrate, fumarate, and pyruvate. Phosphoserine, the direct precursor of serine, was also decreased in B6-deficient cells. The masses of the features that were increased corresponded to those of glutamine and glutamine adducts (Tables 1 and 2). This increase was confirmed by targeted LC-MS/MS (Suppl. Fig. S2a).

The most striking observations were the decreased signals of serine and glycine, two amino acids that are increased in plasma of vitamin B6-deficient patients and animal models. Thus, we confirmed the amino acid findings by quantitative...
Table 1  The 15 most significantly altered intracellular compounds (positive scan mode)

| # | m/z     | Identification                                                                 | P value   | Change | Fold change a |
|---|---------|--------------------------------------------------------------------------------|-----------|--------|---------------|
| 1 | 144.006 | serine [M + K]^+                                                               | 5.82E-13  | decrease 2.7 |
| 2 | 106.050 | serine [M]^+                                                                   | 3.95E-13  | decrease 2.2 |
| 3 | 223.075 | L-cystathionine [M]^+; cysteinyl-threonine [M]^+; threonyl-cysteine [M]^+        | 4.57E-13  | decrease 4.0 |
| 4 | 128.032 | serine [M + Na]^+                                                              | 2.87E-12  | decrease 1.8 |
| 5 | 104.070 | (α/β/γ)-aminobutyric acid [M]^+; dimethylglycine [M]^+                          | 5.14E-12  | decrease 1.5 |
| 6 | 165.988 | serine [M + NaK-H]^+                                                           | 8.90E-11  | decrease 3.0 |
| 7 | 150.014 | serine [M + 2Na-H]^+                                                           | 4.85E-10  | increase 1.9 |
| 8 | 207.014 | glutamine [M + NaK-H]^+                                                         | 8.50E-09  | increase 1.2 |
| 9 | 157.011 | malic acid [M + Na]^+                                                           | 2.82E-08  | decrease 1.3 |
| 10| 178.993 | malic acid [M + 2Na-H]^+                                                        | 3.75E-08  | decrease 1.3 |
| 11| 215.016 | citric acid [M + Na]^+; isocitric acid [M + Na]^+                               | 4.21E-08  | decrease 1.2 |
| 12| 76.039  | glycine [M]^+                                                                   | 5.51E-08  | decrease 1.4 |
| 13| 135.977 | glycine [M + NaK-H]^+                                                           | 9.44E-08  | increase 1.7 |
| 14| 191.040 | glutamine [M + 2Na-H]^+                                                         | 3.42E-07  | increase 1.4 |
| 15| 113.995 | glycine [M + K]^+                                                               | 6.88E-07  | decrease 1.4 |

Direct infusion high resolution mass spectrometry (DI-HRMS) in positive scan mode was used to detect the overall intracellular metabolic consequence of vitamin B6 deprivation. A t-test was performed on the area under the curve (AUC, in a plot of intensities against time) for every compound. Compounds are sorted on the P value between PL absence and presence (100 nM)

a Fold change was calculated from the arithmetic mean values of the AUC of each group

Table 2  The 15 most significantly altered intracellular compounds (negative scan mode)

| # | m/z     | Identification                                                                 | P value   | Change | Fold change a |
|---|---------|--------------------------------------------------------------------------------|-----------|--------|---------------|
| 1 | 181.051 | homovanilic acid [M]^+; 4-hydroxyphenyllactic acid [M]^+                        | 2.39E-13  | decrease 1.6 |
| 2 | 104.035 | serine [M]^+                                                                   | 6.67E-12  | decrease 2.6 |
| 3 | 221.060 | L-cystathionine [M]^+; cysteinyl-threonine [M]^+; threonyl-cysteine [M]^+        | 4.48E-11  | decrease 3.8 |
| 4 | 129.056 | 3-methyl-2-ketovaleric acid [M]^+; 4-methyl-2-ketovaleric acid [M]^+             | 5.91E-11  | decrease 2.1 |
| 5 | 215.033 | hexose [M + Cl]^−                                                              | 6.98E-13  | decrease 1.4 |
| 6 | 87.009  | pyruvic acid [M]^−                                                             | 2.31E-10  | decrease 1.5 |
| 7 | 181.039 | glutamine [M + Cl]^−                                                           | 6.09E-10  | increase 1.3 |
| 8 | 140.012 | O-phosphoethanolamine, serine [M + Cl]^−; α/β/γ-aminobutyric acid [M + K-H]^+; dimethylglycine [M + K-H]^+ | 2.24E-09  | decrease 2.9 |
| 9 | 184.002 | phosphoserine [M]^+                                                            | 1.08E-08  | decrease 3.5 |
| 10| 145.062 | glutamine [M]^+; uridoisobutyric acid [M]^+; alanyl-glycine [M]^+                | 2.53E-08  | increase 1.3 |
| 11| 195.051 | gluconic acid [M]^+; galactonic acid [M]^+                                      | 3.20E-08  | increase 1.2 |
| 12| 218.033 | 3-methyladipic acid [M]^−; pinellic acid [M + NaCl]^−                           | 1.06E-07  | decrease 1.4 |
| 13| 190.973 | glycolaldehyde-3-P [M + Na-H]^+                                                | 1.13E-07  | decrease 1.3 |
| 14| 243.038 | glutamine [M + H_2PO_4]^−                                                      | 2.37E-07  | increase 1.3 |
| 15| 150.980 | maleic acid [M]^+; fumaric acid [M]^+                                          | 7.49E-07  | decrease 1.4 |

Direct infusion high resolution mass spectrometry (DI-HRMS) in negative scan mode was used to detect the overall intracellular metabolic consequence of vitamin B6 deprivation. A t-test was performed on the area under the curve (AUC, in a plot of intensities against time) for every compound. Compounds are sorted on the P value between PL absence and presence (100 nM)

a Fold change was calculated from the arithmetic mean values of the AUC of each group
LC-MS/MS (Fig. 1 and S2). The intracellular amino acid fluctuations observed along the course of the study were due to the media refreshment schedule. Media was refreshed every 24 h before sampling. As a consequence, cells were exposed to the same medium for 2 or 3 days, depending on the collection time point. Nevertheless, intracellular serine concentrations were significantly lower ($P < 0.01$) at all time points, while intracellular glycine concentrations were lower at $t = 4, 11, 14$ and $18$ days ($P < 0.01$, $P < 0.01$, $P < 0.01$ and $P < 0.05$, respectively). Reasoning that the decrease of serine could be either due to reduced biosynthesis or reduced import from the culture medium, we analysed serine and glycine concentrations in the medium that was sampled from the cells during the experiment (Fig. 1). In the presence of 100 nM PL, cells were found to have net export of serine into the medium at later time points. In contrast, in vitamin B6-deficient cells import of serine from the medium exceeds export. Glycine is exported, both in PL presence and absence but vitamin B6-deficient cells exported 17–21% less glycine than cells cultured in 100 nM PL. This suggests that biosynthesis of serine is hampered when cells are deficient in vitamin B6, making them more dependent on extracellular serine. This proposition is strengthened by the decrease of phosphoserine, the immediate precursor of serine, observed in the untargeted metabolomics analysis (Table 2).

Cystathionine was strongly decreased in B6-deficient conditions. Cystathionine is an intermediary metabolite in the homocysteine transsulfuration pathway. Cystathionine β-synthase (CBS, EC 4.2.1.22), the first enzyme in the homocysteine transsulfuration pathway, catalyzes cystathionine synthesis from homocysteine and serine, using pyridoxal 5'-phosphate as cofactor. Our results suggest that the additive effects of vitamin B6 and serine deficiencies led to a strong decrease of cystathionine production.

Serine biosynthesis is decreased when vitamin B6 is deficient

To investigate serine de novo biosynthesis we performed a metabolic flux analysis. Vitamin B6-deficient and -proficient cells were incubated with $^{13}$C$_6$-glucose. In the vitamin B6 deficiency condition, serine synthesis was significantly decreased ($P < 0.05$) with a 50% reduction at $t = 12$ h. Intracellular $^{13}$C$_2$-glycine concentrations were significantly decreased at $t = 0.5$ ($P < 0.01$) and $12$ h ($P < 0.05$), being 38% less in the B6-deficient cells at $t = 12$ h (Fig. 2).

We analysed the intracellular concentrations of 5-mTHF, the other product of SHMT activity, in addition to glycine, and established they were significantly decreased at $t = 1$ and 3 days ($**P < 0.01$, and $*P < 0.05$, respectively) in vitamin B6-deficient cells (Fig. 2).

Discussion

Vitamin B6 has an important role in development and functioning of the brain by catalyzing essential reactions in neurotransmitter and amino acid metabolism (Surtees et al 2006). To investigate the metabolic consequences of vitamin B6 deficiency in the brain, we employed a model system of Neuro-2a cells that were cultured in vitamin B6-deficient medium. Neuro-2a cells have a neuronal origin and are easily cultured in high amounts. In previous (yet unpublished) work we have investigated the presence of the enzymes involved in vitamin B6 metabolism and found that all are present in these cells, confirming that they provide a suitable model. This model mimics vitamin B6 deficiency as it results in strongly decreased intracellular concentrations of PLP (63% reduction at the latest time point) and PMP (50% reduction at the latest time point). The low PLP is a direct consequence of PL absence in the medium, whereas the decrease of PMP may reflect less transaminating activity secondary to the low PLP. It is unknown how the brain intracellular concentrations of vitamin B6 relate between B6-deficient and B6-proficient humans. However, some in vivo animal studies have documented vitamin B6 levels in the brain of B6-deficient animals. In Dakshinamurti et al, adult rats were fed PN-supplemented and PN-deficient diets and the PLP concentrations in the brains were documented. In the whole brain of B6-deficient rats, PLP concentrations were 28% reduced, while in their hypothalamus the reduction was 57% compared to PN-supplemented (control) rats (Dakshinamurti et al 1985). These results are in close accordance with the ones presented in this study. Thus, we successfully created a vitamin B6 deficiency model system.

Investigation of metabolism by untargeted metabolomics yielded a range of altered metabolites: amino acids, Krebs cycle intermediates, GABA and homovanillic acid. Among the most significantly changed metabolites were serine and glycine, which were both decreased as validated by targeted LC-MS/MS analysis. Flux studies clearly illustrated reduced serine biosynthesis in vitamin B6-deficient Neuro-2a cells and thus made evident that serine biosynthesis depends on vitamin B6. The PLP-dependent enzyme phosphoserine aminotransferase (PSAT, EC 2.6.1.52) cannot fully function in vitamin B6 deficient conditions, which is expected to result in less synthesis of phosphoserine and serine, as observed.

The low medium and intracellular serine concentrations are in contrast with reports on the effect of vitamin B6 deprivation on human plasma, in which the concentrations of glycine showed an increase of 28% after 2 weeks of vitamin B6 depletion and serine showed an increase of 47% after 1 week of depletion (Park and Linkswiler 1971). This behaviour was also observed in a 28-day vitamin B6 restriction diet study, where the plasma levels of healthy men and women for glycine and serine showed an increase of 15% and 12%,
respectively (da Silva et al 2013). Furthermore, cerebrospinal fluid (CSF) studies of PNPO-deficient patients have reported elevated levels of glycine prior to B6 supplementation (Mills et al 2005). For the one individual in this study in whom CSF

Fig. 1  Serine and glycine levels are decreased in vitamin B6-deficient cells. Neuro-2a cells were grown in medium in the presence (100 nM) and absence of PL for 18 days. Extracellular serine and glycine concentrations are presented as the difference to the media basal amino acid levels. Intracellular concentrations are normalized to total protein content. All results are represented as the mean of triplicates ± SD; * P < 0.05, ** P < 0.01

Fig. 2  Vitamin B6 deficiency hampers serine \textit{de novo} biosynthesis and decreases 5-methyltetrahydrofolate levels. Neuro-2a cells were grown in medium in the presence (100 nM) and absence of PL for 3 days. On day 3 cells were incubated with \textsuperscript{13}C\textsubscript{6}-glucose, and the formation of the labelled \textsuperscript{13}C\textsubscript{3}-serine and \textsuperscript{13}C\textsubscript{2}-glycine was analysed at t = 0.5, 4 and 12 h after exposure. Results are represented as the mean of triplicates ± SD. The insert reflects the steady state levels of 5-methyltetrahydrofolate. For 5-methyltetrahydrofolate study, Neuro-2a cells were grown in medium in the presence (100 nM) and absence of PL for 3 days. The results are normalized to total protein content and represented as the mean of \( n = 6 \) (t = 1 day) and \( n = 12 \) (t = 3 days) ± SD; * P < 0.05, ** P < 0.01
analysis was repeated after supplementation this normalized. Elevation of CSF glycine has been reported to occur secondary to a deficiency of the activity of the glycine cleavage system, which is PLP-dependent. It should be noted however that this does not occur in all PNPO-deficient patients, with some only showing a transient increase of glycine in CSF (Hoffmann et al 2007). Glycine levels have also been reported to be slightly raised in the CSF of patients with mutations in PROSC prior to B6-supplementation (Darín et al 2016). In patients with mutations in ALDH7A1, however, CSF glycine levels have been reported to be normal (Hoffmann et al 2007) or just slightly elevated (Mills et al 2010). Interestingly few studies report on serine levels leading us to assume that serine is kept within normal values in the CSF of vitamin B6 deficient patients. Additionally, in a B6-deprivation study in HepG2 cells, vitamin B6 deficiency yielded large increases in glycine concentrations and no effect on serine (da Silva et al 2014). However, our findings in the Neuro-2a model are in accordance with in vivo studies performed by Tews, in which mice fed on a PN-deficient diet for 4 weeks presented a progressive decrease in brain serine concentrations. Brain glycine concentrations significantly decreased during the first 2 weeks of PN-deprivation and increased after 4 weeks when compared to normal-PN fed mice. Upon reinstating a complete-PN diet, serine and glycine concentrations returned to control levels (Tews 1969). This suggests that a decrease in serine and concomitant decrease in glycine concentrations is tissue or cell type dependent.

Serine in brain originates from two sources: uptake and biosynthesis (de Koning et al 2003). Serine de novo biosynthesis is a side-pathway of glycolysis. The first and rate-limiting step is the oxidation of 3-phosphoglycerate (3-PG) to 3-phosphohydroxypyruvate, by 3-phosphoglycerate dehydrogenase (PHGDH, EC 1.1.1.95). The conversion of 3-phosphohydroxypyruvate to 3-phosphoserine is catalyzed by phosphoserine aminotransferase, a PLP-dependent enzyme. Serine biosynthesis seems to be particularly important in the brain, as illustrated by the severe clinical symptoms in patients affected with a defect in serine synthesis, including congenital microcephaly, severe epilepsy and very little development (Jaeken et al 1996; Furuya 2008). In CSF of these patients, serine (both L- and D-serine) and glycine are decreased (van der Crabben et al 2013).

Glycine production depends on serine availability and on the PLP-dependent enzyme SHMT. SHMT catalyzes the transfer of the methyl group of serine to tetrahydrofolate (THF), allowing the formation of 5,10-methylene tetrahydrofolate (5,10-methyleneTHF) and glycine (de Koning et al 2003). 5,10-methyleneTHF is converted by the enzyme methylene tetrahydrofolate reductase (MTHFR, EC 1.5.1.20) to 5-mTHF, the main circulating form of folate which can serve as a methyl donor in the generation of S-adenosylmethionine (SAM). Indeed, the combination of less serine and PLP may lead to a lower activity of SHMT, explaining the decrease in the intracellular concentration of 5-mTHF in vitamin B6-deficient cells.

Our findings are important in considering pathogenesis and treatment of patients with vitamin B6-dependent epilepsy. Generally, it was thought that a reduction of GABA concentrations in the brain of these patients was the main cause of the epilepsy, due to suboptimal activity of the PLP-dependent enzyme glutamic acid decarboxylase. We demonstrate that low serine, glycine and 5-methyltetrahydrofolate may also contribute to pathogenesis. Probably, these amino acids are low in brain cells in vivo, as suggested by the B6-deficient mouse studies (Tews 1969). Although theoretically uptake of serine and glycine from blood to brain may compensate a lower serine biosynthetic capacity, two observations suggest clinical relevance of our findings. Patients with a defect in serine synthesis need high doses of serine to normalize serine in CSF (de Koning et al 2003; van der Crabben et al 2013). Furthermore, some patients with vitamin B6-dependent epilepsy clinically respond to supplementation of folinic acid, a 5-mTHF precursor (Nicolaï et al 2006; Gallagher et al 2009; Stockler et al 2011; Dill et al 2011; van Karnebeek et al 2016).

Our work provides an explanation for this hitherto puzzling observation.

**Materials and methods**

**Cell culture**

Neuro-2a cells were purchased from ATCC Cell Biology Collection. Dulbecco’s modified eagle medium (DMEM) GlutaMAX™ (31966), B6 vitamer-free DMEM GlutaMAX™ (custom made 31966-like) medium, foetal bovine serum (FBS; 10270), penicillin-streptomycin (P/S; 15140) and trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA, 0.5%) were purchased from Gibco (Invitrogen Life Technologies). Pyridoxal hydrochloride (PL-HCl) was purchased from Sigma-Aldrich (Steinheim, Germany). Cells were grown in 75 cm² flasks and maintained in DMEM GlutaMAX™ supplemented with 10% heat-inactivated FBS and 1% P/S, in a humidified atmosphere of 5% CO₂ at 37 °C. When cells reached optimal confluence (>70%) they were washed twice with PBS and passed into 6-well plates (1.5 × 10⁵ cells per well) by trypsinization with 0.05% trypsin-EDTA. Confluent cells (>70%) were exposed to the experimental medium conditions: 1:1, PBS:B6 vitamer-free DMEM GlutaMAX™ (with 10% FBS and 1% P/S), with 100 nM of PL-HCl (content of vitamin B6: PL 97.4 ± 5.6 nM; PN 2.6 ± 2.6 nM; PM 1.4 ± 1.3 nM; PLP 1.9 ± 1.5; PNP and PMP are below the LOQ) or without vitamin B6 (residual content of vitamin B6: PL...
4.7 ± 3.8 nM; PN 2.3 ± 0.4 nM; PM 1.1 ± 1.1 nM; PLP, PNP and PMP are below the LOQ).

**Vitamin B6 vitamers**

Vitamin B6 vitamers were quantified according to the method of van der Ham et al (2012).

**Direct-infusion high-resolution mass spectrometry (DI-HRMS)**

Direct-infusion was performed using chip-based infusion (400 nozzles, nominal internal Ø 5 μm) on the TriVersa NanoMate (Advion, Ithaca, NY, USA). High-resolution mass spectrometry (140,000) was performed using a Q-ExactivePlus (Thermo Scientific GmbH, Bremen, Germany) using a scan range of m/z 70 to 600 in positive and negative modes. Besides mass calibration of the instrument, internal lock masses were used for high mass accuracy. Cells were harvested in biological triplicates.

**Untargeted metabolomics pipeline (DI-HRMS)**

RAW data files were converted to mzXML format using MSConvert (Chambers et al 2012). The data were processed using an in-house developed untargeted metabolomics pipeline written in the R programming language (http://www.r-project.org). First, the mzXML files were converted to readable format by the XCMS package (Smith et al 2006). For every sample, peak finding was done and peaks with the same m/z (within 0.5*fwhm) were grouped over different samples. Peak groups that were not present in three out of three technical replicates in at least one biological sample were discarded. The intensities of the technical replicates were averaged. Peak groups were identified using all entries in the HMDB, including their most likely adducts (Na+, K+, NH4+ in positive mode and Cl− and formate in negative mode) and isotopes, using an accuracy of 3 ppm or better. The statistical analysis was a t-test on the area under the curve (AUC) in a plot of intensities against time for every metabolite. Raw metabolomics data can be supplied upon request.

**Ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS)**

**Amino acids**

Amino acid concentrations were determined using the UPLC-MS/MS method described by Prinsen et al (2016). Apart from adapting the range of the calibrators and quality control (QC) samples to resemble the concentrations in the samples, no further adaptations were needed for sample preparation or analysis of the amino acids.

**Vitamin B6 vitamers**

Vitamin B6 vitamers were quantified according to the method of van der Ham et al (2012).

5-methyltetrahydrofolate (5-mTHF)

5-mTHF was purchased from Sigma-Aldrich (Steinheim, Germany). The internal standard 13C5–5-mTHF was purchased from Merck KGaA (Darmstadt, Germany). 5-mTHF analyses were performed on a Waters Micromass Quattro Ultima triple quadrupole mass spectrometer (Manchester, U.K.), using an Acquity UPLC™ BEH C18 (130 Å, 17 μm 2.1 × 50 mm column) (Waters, Manchester, UK), which was kept at 30 °C, while the autosampler temperature was kept at 15 °C. The dwell time was set at 0.3 s. The capillary voltage was 3.00 kV and the cone voltage was 35 V. The source and desolvation temperatures were 120 and 450 °C respectively. The cone gas flow rate was 158 L/h. Quantitative analysis was achieved using a negative ion multiple reaction monitoring (MRM) mode with the m/z transitions of 460.2 > 313.2 and 465.2 > 313.2 with a collision energy of 17 and 18 V, for 5-mTHF and 13C5–5-mTHF respectively. The specific MRM transitions were determined by direct infusion of both standards and internal standards.

**Metabolic flux analysis: serine de novo biosynthesis**

**Protein analysis**

Protein concentrations were quantified using the 96-well microplate protocol of the colorimetric bicinechonic acid (BCA) Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific Incorporated), in accordance with the manufacturer’s protocol, with BSA as standard.

**Statistical analysis**

Statistical significance was determined with unpaired two-tailed t-test, using GraphPad Prism 6 (version 6.0.2, GraphPad Software Inc.) software.
Acknowledgements We would like to thank Marjolein Bosma and Birgit Schieberring-Bronkhorst for their technical assistance. This work was funded by Metakids foundation (www.metakids.nl).

Funding on financial relationships This work was funded by Metakids foundation (www.metakids.nl).

Compliance with ethical standards Conflict of interest R. Ramos, M. Pras-Raves, J. Gerrits, M. van der Ham, M. Willemsen, H. Prinsen, B. Burgering, J. Jans, and N. Verhoeven-Duif declare that they have no conflict of interest.

Informed consent This article does not contain any studies with human or animal subjects performed by the any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Baumeister FA, Gsell W, Shin YS, Egger J (1994) Glutamate in pyridoxine-dependent epilepsy: neurotoxic glutamate concentration in the Cerebrospinal fluid and its normalization by pyridoxine. Pediatrics 94:318–321

Baxter P (1999) Epidemiology of pyridoxine dependent and pyridoxine responsive seizures in the UK. Arch Dis Child 81:431–433

Baxter P (2001) Pyridoxine-dependent and pyridoxine responsive seizures. Dev Med Child Neurol 43:416–420

Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egerton J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak M-Y, Paulse C, Creasy D, Flasher L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kahlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus DB, MacCoss M, Tabb DL, Mallick P (2012) A Cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol 30(10):918–920

Clayton PT (2006) B6-responsive disorders: a model of vitamin dependence. J Inherit Metab Dis 29(2–3):317–326

da Silva VR, Rios-Avila L, Lamers Y, Ralat MA, Midtun Ø, Quinlivan EP, Garrett TJ, Coats B, Shankar MN, Percival SS, Chi YY, Muller KE, Ueland PM, Staapoe PW, Gregory JF (2013) Metabolite profile analysis reveals functional effects of 28-day vitamin B-6 restriction on one-carbon metabolism and tryptophan catabolic pathways in healthy men and women. J Nutr 143(11):1719–1727

da Silva VR, Ralat MA, Quinlivan EP, DeRatt BN, Garrett TJ, Chi Y-Y, Reed MC, Gregory JF (2014) Targeted metabolomics and mathematical modeling demonstrate that vitamin B-6 restriction alters one-carbon metabolism in cultured HepG2 cells. Am J Physiol Endocrinol Metab 307(1):E93–101

Dakshinamurti K, Paulose CS, Siow YL (1985) Neurobiology of pyridoxine. In: Reynolds RD, Leklem JE (eds) Vitamin B6: its role in health and disease. AR Liss, New York, pp 99–121

Darin N, Reid E, Prunetti L, Samuelsson L, Husain RA, Wilson M, El Yacoubi B, Footitt E, Chong WK, Wilson LC, Prunty H, Pope S, Heales S, Lascelles K, Champion M, Wassmer E, Veggioit P, de Crécy-Lagard V, Mills PB, Clayton PT (2016) Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-B6-dependent epilepsy. Am J of Hum Genet 99(6):1235–1327

de Koning TJ, Snell K, Duran M, Berger R, Poll-The BT, Surtees R (2003) L-serine in disease and development. Biochem J 371:653–661

De Roo MG, Abeling NG, Majoie CB, Bosch AM, Koelman JH, Cobben JM, Duran M, Poll-The BT (2014) Infantile hypophosphatasia without bone deformities presenting with severe pyridoxine-resistant seizures. Mol Genet Metab 111(3):404–407

Dill P, Schneider J, Weber P, Trachsel D, Tekin M, Jakobs C, Thöny B, Blau N (2011) Pyridoxal phosphate-responsive seizures in a patient with cerebral folate deficiency (CFD) and congenital deafness with labyrinthine aplasia, microtia and microdontia (LAMM). Mol Genet Metab 104(3):362–368

Ebadi M (1981) Regulation and function of pyridoxal phosphate in cns. Neurochem Int 3:181–206

Furuya S (2008) An essential role for de novo biosynthesis of L-serine in CNS development. Asia Pac J Clin Nutr 17(S1):312–315

Gallagher RC, Van Hove JL, Schurer G, Hyland K, Plecko B, Waters PJ, Mercimek-Mahmutoglu S, Stockler-Ipsiroglu S, Salomons GS, Rosenberg EH, Struys EA, Jakobs C (2009) Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol 65(5):550–556

Gospe SM Jr, Olin KL, Keen CL (1994) Reduced GABA synthesis in pyridoxine-dependent seizures. Lancet 343:1133–1134

Goto T, Matsuo N, Takahashi T (2001) CSF glutamate/GABA concentrations in pyridoxine-dependent seizures: etiology of pyridoxine-dependent seizures and the mechanisms of pyridoxine action in seizure control. Brain and Development 23:24–29

Hoffmann GF, Schmitt B, Windfuhr M, Wagner N, Strehl H, Bagci S, Franz AR, Mills PB, Clayton PT, Baumgartner MR, Steinnmann B, Bast T, Wolf NI, Zschocke J (2007) Pyridoxal 5′-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis 30(1):96–99

Jaeken J, Detheux M, Van Maldergem L, Foulon M, Carchon H, Van Schaftingen E (1996) 3-phosphoglycerate dehydrogenase deficiency: inborn error of serum biosynthesis. Arch Dis Child 74:542–545

Lee GH, Sung SY, Chang WN, Kao TT, Du HC, Hsiao TH, Safo MK, Fu TF (2012) Zebrafish larvae exposed to ginkgotoxin exhibit seizure-like behavior that is relieved by pyridoxal-5′-phosphate, GABA and anti-epileptic drugs. Dis Model Mech 5(6):785–795

Levotova A, Camuzeaux S, Laberge AM, Allard P, Brunel-Guittton C, Diadodi P, Rossignol E, Hyland K, Clayton PT, Mills PB, Mitchell GA (2015) Normal cerebrospinal fluid pyridoxal 5′-phosphate level in a PNPO-deficient patient with neonatal-onset epileptic encephalopathy. JIMD Rep 22:67–75

Mills PB, Surtees RA, Champion MP, Beesley CE, Dalton N, Scambler PJ, Heales SJ, Briddon A, Scheimbirg I, Hoffmann GF, Zschocke J, Clayton PT (2005) Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase. Hum Mol Genet 14(8):1077–1086

Mills PB, Footitt EJ, Mills KA, Tuschl K, Aylett S, Varadkar S, Hemingway C, Marlow N, Remijie J, Baxter P, Dulac O, Nabbout R, Craigin WJ, Schmitt B, Footitt E, Christensen E, De Lonlay P, Pike MG, Hughes ME, Struys EA, Jakobs C, Zuberi SM, Clayton PT (2010) Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 133(7):2148–2159

Mills PB, Camuzeaux SS, Footitt EJ, Mills KA, Gissen P, Fisher L, Das KB, Varadkar SM, Zuberi S, McWilliam R, Stödberg T, Plecko B, Baumgartner MR, Maier O, Calvert S, Riney K, Wolf NL, Livingston JH, Bala P, Morel CF, Footitt E, Raimondi F, Del Giudice E, Chong WK, Pitt M. Clayton PT (2014) Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain 137(5):1350–1360
Nicolai J, van Kranen-Mastenbroek VH, Wevers RA, Hurks WA, Vles JS (2006) Folinic acid-responsive seizures initially responsive to pyridoxine. Pediatr Neurol 34(2):164–167

Park YK, Linkswiler H (1971) Effect of vitamin B6 depletion in adult man on the plasma concentration and the urinary excretion of free amino acids. J Nutr 101(2):185–191

Prinsen HC, Schiebergen-Bronkhorst BG, Roeleveld MW, Jans JJ, de Sain-van der Velden MG, Visser G, van Hasselt PM, Verhoeven-Duif NM (2016) Rapid quantification of underivatized amino acids in plasma by hydrophilic interaction liquid chromatography (HILIC) coupled with tandem mass-spectrometry. J Inherit Metab Dis 39(5):651–660

Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G (2006) XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78(3):779–787

Stockler S, Plecko B, Gospe SM Jr, Coulter-Mackie M, Connolly M, van Karnebeek C, Mercimek-Mahmutoglu S, Hartmann H, Scharer G, Struijs E, Tein I, Jakobs C, Clayton P, Van Hove JL (2011) Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 104(1–2):48–60

Surtees R, Mills P, Clayton P (2006) Inborn errors affecting vitamin B6 metabolism. Future Neurol 1(5):615–620

Tews JK (1969) Pyridoxine deficiency and brain amino acids. Ann N Y Acad Sci 166(1):74–82

Uleland PM, Ulvik A, Rios-Avila L, Midttun Ø, Gregory JF (2015) Direct and functional biomarkers of vitamin B6 status. Ann Rev Nutr 35:33–70

van der Crabben SN, Verhoeven-Duif NM, Brilstra EH, Van Maldergem L, Coskun T, Rubio-Gozalbo E, Berger R, de Koning TJ (2013) An update on serine deficiency disorders. J Inherit Metab Dis 36(4):613–619

van der Ham M, Albersen M, de Koning TJ, Visser G, Middendorp A, Bosma M, Verhoeven-Duif NM, de Sain-van der Velden MG (2012) Quantification of vitamin B6 vitamers in human cerebrospinal fluid by ultra performance liquid chromatography-tandem mass spectrometry. Anal Chim Acta 712:108–114

van Karnebeek CDM, Tiebout SA, Niermeijer J, Poll-The BT, Ghani A, Coughlin CR, Van Hove JLK, Richter JW, Christen HJ, Gallagher R, Hartmann H, Stockler-Ipsiroglu S (2016) Pyridoxine-dependent epilepsy: an expanding clinical spectrum. Pediatr Neurol 59:1–7

Walker V, Mills GA, Peters SA, Merton WL (2000) Fits, pyridoxine, and hyperprolinaemia type II. Arch Dis Child 82(3):236–237